- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1391KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 302KB)
Cemiplimab – November 2021
Cemiplimab: Solution for I.V. infusion 350 mg in 7 mL; Libtayo®
Last updated
4 March 2022